322 related articles for article (PubMed ID: 10520974)
1. Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors.
Nurnberg HG; Thompson PM; Hensley PL
J Clin Psychiatry; 1999 Sep; 60(9):574-9. PubMed ID: 10520974
[TBL] [Abstract][Full Text] [Related]
2. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.
Kroenke K; West SL; Swindle R; Gilsenan A; Eckert GJ; Dolor R; Stang P; Zhou XH; Hays R; Weinberger M
JAMA; 2001 Dec; 286(23):2947-55. PubMed ID: 11743835
[TBL] [Abstract][Full Text] [Related]
3. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline.
Ball SG; Kuhn A; Wall D; Shekhar A; Goddard AW
J Clin Psychiatry; 2005 Jan; 66(1):94-9. PubMed ID: 15669894
[TBL] [Abstract][Full Text] [Related]
4. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
Shih YC; Bekele NB; Xu Y
Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
[TBL] [Abstract][Full Text] [Related]
5. Long-term costs of treatment for depression: impact of drug selection and guideline adherence.
Crown WH; Treglia M; Meneades L; White A
Value Health; 2001; 4(4):295-307. PubMed ID: 11705297
[TBL] [Abstract][Full Text] [Related]
6. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.
Peveler R; Kendrick T; Buxton M; Longworth L; Baldwin D; Moore M; Chatwin J; Goddard J; Thornett A; Smith H; Campbell M; Thompson C
Health Technol Assess; 2005 May; 9(16):1-134, iii. PubMed ID: 15876362
[TBL] [Abstract][Full Text] [Related]
7. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.
Russell JM; Berndt ER; Miceli R; Colucci S; Grudzinski AN
Am J Manag Care; 1999 May; 5(5):597-606. PubMed ID: 10537866
[TBL] [Abstract][Full Text] [Related]
8. Modeling the pharmacoeconomic cost of three selective serotonin reuptake inhibitors.
Nurnberg HG; Hensley PL; Thompson PM; Paine SS
Psychiatr Serv; 1999 Oct; 50(10):1351-3. PubMed ID: 10506306
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy for anxiety and comorbid alcohol use disorders.
Ipser JC; Wilson D; Akindipe TO; Sager C; Stein DJ
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD007505. PubMed ID: 25601826
[TBL] [Abstract][Full Text] [Related]
10. Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans.
Polsky D; Onesirosan P; Bauer MS; Glick HA
J Clin Psychiatry; 2002 Feb; 63(2):156-64. PubMed ID: 11874218
[TBL] [Abstract][Full Text] [Related]
11. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram.
Mullins CD; Shaya FT; Meng F; Wang J; Harrison D
Pharmacotherapy; 2005 May; 25(5):660-7. PubMed ID: 15899727
[TBL] [Abstract][Full Text] [Related]
12. The pharmacoepidemiology of selective serotonin reuptake inhibitors for children and adolescents in Canada from 2005 to 2009: a database analysis.
Lam D; Gorman DA; Patten S; Pringsheim T
Paediatr Drugs; 2013 Aug; 15(4):319-27. PubMed ID: 23529865
[TBL] [Abstract][Full Text] [Related]
13. Length of therapy with selective serotonin reuptake inhibitors and tricyclic antidepressants in Australia.
McManus P; Mant A; Mitchell P; Dudley J
Aust N Z J Psychiatry; 2004 Jun; 38(6):450-4. PubMed ID: 15209838
[TBL] [Abstract][Full Text] [Related]
14. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277
[TBL] [Abstract][Full Text] [Related]
15. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment.
Fava M; Judge R; Hoog SL; Nilsson ME; Koke SC
J Clin Psychiatry; 2000 Nov; 61(11):863-7. PubMed ID: 11105740
[TBL] [Abstract][Full Text] [Related]
16. Economic appraisal of citalopram in the management of single-episode depression.
Sclar DA; Skaer TL; Robison LM; Galin RS
J Clin Psychopharmacol; 1999 Oct; 19(5 Suppl 1):47S-54S. PubMed ID: 10507508
[TBL] [Abstract][Full Text] [Related]
17. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
[TBL] [Abstract][Full Text] [Related]
18. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
[TBL] [Abstract][Full Text] [Related]
19. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
Hjalmarsson L; Corcos M; Jeammet P
Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
[TBL] [Abstract][Full Text] [Related]
20. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis.
Hylan TR; Crown WH; Meneades L; Heiligenstein JH; Melfi CA; Croghan TW; Buesching DP
J Affect Disord; 1998 Jan; 47(1-3):71-9. PubMed ID: 9476746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
